Flynn J T, Pasko D A
Department of Pediatrics and Communicable Diseases, C.S. Mott Children's Hospital, University of Michigan, Ann Arbor, Michigan, USA.
Pediatr Nephrol. 2000 Dec;15(3-4):302-16. doi: 10.1007/s004670000480.
The calcium channel blockers (CCBs) are a diverse group of antihypertensive medications with variable pharmacokinetics and clinical effects. Although CCBs have been widely applied to the treatment of hypertensive children, data regarding the pharmacokinetics, efficacy and safety of these agents in children are extremely limited. In this review we briefly summarize the mechanism of action of CCBs and then summarize pertinent pharmacokinetic information on each of the CCBs commonly used in children, including amlodipine, diltiazem, felodipine, isradipine, intravenous nicardipine, nifedipine and verapamil. Clinically important drug interactions and adverse effects are discussed, as well as the potential role of CCBs in renal protection. Available pediatric efficacy and safety data are summarized, and recommendations made regarding the rational use of CCBs in the management of pediatric hypertension.
钙通道阻滞剂(CCB)是一类多样的抗高血压药物,其药代动力学和临床效果各不相同。尽管CCB已广泛应用于儿童高血压的治疗,但关于这些药物在儿童中的药代动力学、疗效和安全性的数据极为有限。在本综述中,我们简要总结了CCB的作用机制,然后总结了儿童常用的每种CCB的相关药代动力学信息,包括氨氯地平、地尔硫䓬、非洛地平、伊拉地平、静脉用尼卡地平、硝苯地平和维拉帕米。讨论了临床上重要的药物相互作用和不良反应,以及CCB在肾脏保护中的潜在作用。总结了现有的儿科疗效和安全性数据,并就CCB在儿童高血压管理中的合理使用提出了建议。